Epicyt Pharma Reports Positive Phase 1/2a Results for BAFA in Post-Gastric Bypass Patients
Epicyt Pharma study shows statistically significant reduction in urinary calcium excretion and improvements in calcium homeostasis biomarkers, supporting planned Phase 2b development.
Bariatric Surgery | 09/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy